Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) released its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, Zacks reports.
Eupraxia Pharmaceuticals Trading Down 2.7 %
Shares of EPRX stock opened at $3.91 on Friday. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $4.48. The stock has a market capitalization of $139.38 million and a price-to-earnings ratio of -5.43. The stock has a fifty day simple moving average of $3.47 and a two-hundred day simple moving average of $3.09.
Wall Street Analysts Forecast Growth
Separately, Craig Hallum assumed coverage on Eupraxia Pharmaceuticals in a research report on Friday, February 21st. They set a “buy” rating and a $12.00 target price on the stock.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Lucid’s Stock Comeback—Is a Long-Term Recovery Ahead?
- How Investors Can Find the Best Cheap Dividend Stocks
- BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
